Susquehanna options strategist Alison Edwards notes near-term bearish bias in AstraZeneca (NYSE: AZN), as investors purchased about 3000 Aug 28.5 Puts and 6,000 Aug 30 Puts.

Options Trader Talk

AstraZeneca (AZN) Says IMFINZI Granted Breakthrough Therapy Designation by US FDA for Patients with Locally Advanced Unresectable NSCLCJuly 31, 2017 7:05 AM AstraZeneca (AZN) Announces FDA Breakthrough Therapy Designation for Imfinzi in NSCLSJuly 31, 2017 6:09 AM Morgan Stanley Downgrades AstraZeneca (AZN) to EqualweightJuly 28, 2017 7:55 AM Dividends a worry at drugmakers Astra, GSK after dramatic weekJuly 28, 2017 6:36 AM Merck (MRK) Likely Out as Potential Suitor for TESARO (TSRO) or Clovis (CLVS) After AstraZeneca Collaboration - Credit SuisseJuly 27, 2017 10:01 AM Leerink Partners Downgrades AstraZeneca (AZN) to Market PerformJuly 27, 2017 9:53 AM